Takeda Pharmaceutical Company Limited - Articles and news items

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

Takeda makes €10 million equity investment in TiGenix

Industry news / 22 December 2016 / Niamh Louise Marriott, Digital Editor

TiGenix, has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

TiGenix’s Crohn’s disease drug granted Swiss orphan drug designation

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells for the treatment of complex perianal fistulas in patients with Crohn’s disease that have…

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

Takeda & TiGenix announce Perianal Fistulas trial treatment results for Crohn’s disease

Industry news / 2 August 2016 / Takeda Pharmaceutical Company Limited / TiGenix NV

Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease…

Takeda & Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

Takeda and Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

Industry news / 1 August 2016 / Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.

Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement…

Five-year data from Phase II trial of Adcetris published

Industry news / 19 July 2016 / Victoria White, Digital Content Producer

The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma…

IBD Unmasked – helping to shift perceptions of IBD

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Collaborating with Marvel Custom Solutions, Takeda’s IBD Unmasked initiative features an IBD Super Hero, Samarium, and a graphic novel series…

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

EC extends conditional marketing authorisation for Adcetris

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma…

Takeda enters into licensing agreement for ex-US rights to Cx601

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+